Inventor · disambiguated record
Louis A. Matis
Also filed as: MATIS LOUIS · MATIS LOUIS A
9 granted patents·3 pending applications·676 citations·filing 1994–2020
89Inventor score
Top patents by PatentIndex Score
12 records- 0196US6355245B1C5-specific antibodies for the treatment of inflammatory diseasesALEXION PHARMA INC·Filed 1995·Granted Mar 12, 2002·465 cites·23 claims
- 0293US6982323B1Chimeric proteins for diagnosis and treatment of diabetesALEXION PHARMA INC·Filed 2000·Granted Jan 3, 2006·70 cites·8 claims
- 0393US6074642AUse of antibodies specific to human complement component C5 for the treatment of glomerulonephritisALEXION PHARMA INC·Filed 1994·Granted Jun 13, 2000·117 cites·5 claims
- 0490US7279158B2Methods for the treatment of inflammatory joint diseaseALEXION PHARMA INC·Filed 2005·Granted Oct 9, 2007·18 cites·17 claims
- 0556US7405279B2Chimeric proteins for diagnosis and treatment of diabetesALEXION PHARMA INC·Filed 2005·Granted Jul 29, 2008·0 cites·8 claims
- 0656US7384915B2Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developing type 1 diabetesALEXION PHARMA INC·Filed 2005·Granted Jun 10, 2008·0 cites·16 claims
- 0751US2024166763A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 0846US2021246219A1Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 0943US5891645APorcine E-selectinALEXION PHARMA INC·Filed 1994·Granted Apr 6, 1999·5 cites·6 claims
- 1037US6040428APorcine E-selectinALEXION PHARMA INC·Filed 1999·Granted Mar 21, 2000·1 cites·3 claims
- 1128US2003175267A1Method for the treatment of inflammatory joint diseaseFiled 1997·Application pending·0 cites
- 1226US7041503B2Modified myelin basic protein moleculesALEXION PHARMA INC·Filed 1995·Granted May 9, 2006·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Louis A. Matis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →